AC Immune SA (ACIU) Price & Analysis

Compare

535 Followers

ACIU Stock Chart & Stats

$3.03

-$0.09(-3.07%)

At close: Jan 08 4:00 PM EST

$3.03

-$0.09(-3.07%)

Day’s Range― - ―

52-Week Range$1.43 - $4.00

Previous CloseN/A

Volume13.14K

Average Volume (3M)1.02M

Market Cap

$299.80M

Enterprise Value$161.11M

Total Cash (Recent Filing)$108.47M

Total Debt (Recent Filing)$4.66M

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Mar 12, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding98,943,130

10 Day Avg. Volume2,662,875

30 Day Avg. Volume1,021,903

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.18

Price to Sales (P/S)8.95

P/FCF Ratio3.74

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue36.85

Enterprise Value/Gross Profit36.85

Enterprise Value/Ebitda-2.31

Forecast

1Y Price Target

$12.00

Price Target Upside296.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.87

Revenue Forecast (FY)$5.56M

Bulls Say, Bears Say

Bulls Say

Cash Resources And Operational EfficiencyCash resources of CHF 127.1 million should provide cash for operations through Q3 2027 not including potential payments from partnering.

Safety ProfileA clean safety and tolerability profile is essential and has been demonstrated, addressing challenges faced by antibody approaches.

Vaccine Platform DevelopmentThe upcoming readout for ACI-7104 in Parkinson’s is considered a critical proof-of-concept for AC Immune’s vaccine platform.

Bears Say

Technical RisksThere are still technical risks to these programs as each vaccine-ish therapy makes some guesses over the structure of the toxic species to be cleared.

AC Immune SA News

AC Immune’s Parkinson’s disease candidate shows positive Phase 2 results

AC Immune (ACIU) announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its...

13d ago

ACIU

Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on AC Immune SA. The associated price...

12d ago

ACIU

AC Immune Reports Promising Phase 2 Results for Parkinson’s Therapy

AC Immune SA ( ($ACIU) ) has shared an update. On December 11, 2025, AC Immune SA announced...

13d ago

ACIU

Promising Potential of AC Immune SA’s Vaccine Platform in Parkinson’s Disease: A Buy Rating by Andrew Fein

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on AC Immune SA and keeping the price...

2M ago

ACIU

AC Immune SA Reports Decline in Q3 2025 Financial Results

AC Immune SA ( ($ACIU) ) has shared an announcement. On November 4, 2025, AC Immune SA released...

2M ago

ACIU

AC Immune reports Q3 EPS (CHF 0.16) vs. CHF 0.05 last year

Reports Q3 revenue CHF 939,000 vs. CHF $25.5M last year. Andrea Pfeifer, CEO of AC Immune (ACIU) SA,...

2M ago

ACIU

AC Immune sees cash runway to end of 3Q27

The Company had total cash resources of CHF 108.5 million, composed of CHF 27.7 million in cash and...

2M ago

ACIU

AC Immune reduced workforce by around 30% following strategic review

Following a strategic review by executive management, the Company sharpened its focused investment on its most important assets....

2M ago

ACIU

AC Immune appoints Mummery as Chair of Clinical Advisory Board

AC Immune (ACIU) announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia...

2M ago

ACIU

AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment

AC Immune (($ACIU)) announced an update on their ongoing clinical study. AC Immune is conducting a study titled...

2M ago

ACIU

AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics

AC Immune (($ACIU)) announced an update on their ongoing clinical study. Study Overview: AC Immune is conducting a...

2M ago

ACIU

AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics

AC Immune (($ACIU)) announced an update on their ongoing clinical study. Study Overview: AC Immune is conducting a...

2M ago

ACIU

AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AC Immune SA today and set a price...

2M ago

ACIU

AC Immune announces publication of preclinical data on ACI-19626

AC Immune (ACIU) announced the publication in Nature Communications of preclinical data on its first-in-class brain positron emission...

2M ago

ACIU

ACIU FAQ

What was AC Immune SA’s price range in the past 12 months?

AC Immune SA lowest stock price was $1.43 and its highest was $4.00 in the past 12 months.

What is AC Immune SA’s market cap?

AC Immune SA’s market cap is $299.80M.

When is AC Immune SA’s upcoming earnings report date?

AC Immune SA’s upcoming earnings report date is Mar 12, 2026 which is in 78 days.

How were AC Immune SA’s earnings last quarter?

AC Immune SA released its earnings results on Nov 04, 2025. The company reported -$0.161 earnings per share for the quarter, beating the consensus estimate of -$0.228 by $0.066.

Is AC Immune SA overvalued?

According to Wall Street analysts AC Immune SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AC Immune SA pay dividends?

AC Immune SA does not currently pay dividends.

What is AC Immune SA’s EPS estimate?

AC Immune SA’s EPS estimate is -0.2.

How many shares outstanding does AC Immune SA have?

AC Immune SA has 98,943,130 shares outstanding.

What happened to AC Immune SA’s price movement after its last earnings report?

AC Immune SA reported an EPS of -$0.161 in its last earnings report, beating expectations of -$0.228. Following the earnings report the stock price went up 3.774%.

Which hedge fund is a major shareholder of AC Immune SA?

Currently, no hedge funds are holding shares in ACIU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AC Immune SA Stock Smart Score

Neutral

Fundamentals

Return on Equity

-72.72%

Trailing 12-Months

Asset Growth

-25.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AC Immune SA

AC Immune SA (ACIU) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease and other tau-related disorders. The company specializes in the discovery and development of immunotherapies and small molecules aimed at targeting misfolded proteins that are implicated in neurodegenerative conditions. AC Immune's core products include its proprietary therapeutic candidates and diagnostic tools that leverage its expertise in protein misfolding and aggregation.

AC Immune SA (ACIU) Earnings & Revenues

Historic Earnings Reports

ACIU Stock 12 Month Forecast

Average Price Target

$12.00

▲(296.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.4523076923076923,4.164615384615384,4.876923076923077,5.5892307692307694,6.3015384615384615,7.0138461538461545,7.726153846153847,8.438461538461539,9.150769230769232,9.863076923076923,10.575384615384616,11.287692307692309,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.4523076923076923,4.164615384615384,4.876923076923077,5.5892307692307694,6.3015384615384615,7.0138461538461545,7.726153846153847,8.438461538461539,9.150769230769232,9.863076923076923,10.575384615384616,11.287692307692309,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.4523076923076923,4.164615384615384,4.876923076923077,5.5892307692307694,6.3015384615384615,7.0138461538461545,7.726153846153847,8.438461538461539,9.150769230769232,9.863076923076923,10.575384615384616,11.287692307692309,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >